10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
The announcement of preliminary data from a Phase III clinical trial evaluating casimersen and golodirsen in Duchenne muscular dystrophy (DMD) patients amenable to skipping exons 45 and 53, respectively saw shares of Sarepta Therapeutics rise, 29 March 2019
The growth of the UK’s biotech sector stands in stark and impressive contrast to many other elements of an economy that is being stagnated by financial and economic uncertainty. 28 March 2019
A broker’s report on Alexion Pharmaceuticals has found that the popular perception of the US pharma as the 'Soliris (eculizumab) company' does not do justice to its pipeline. 28 March 2019
Immuno-oncology (I-O) company Elicio Therapeutics has launched with a $30 million financing to treat a range of cancers with a new vaccine and immunotherapy platform. 28 March 2019
Poland-based Selvita, a clinical stage company engaged in the research and development of novel cancer therapies as well as provision of drug discovery and development services, today announced that it plans to separate into two companies. 28 March 2019
London-listed AstraZeneca has received a positive reimbursement decision from the UK’s health technology assessor, for the immuno-oncology product Imfinzi (durvalumab). 28 March 2019
Japanese pharma giant Takeda Pharmaceutical has entered a collaboration and license deal to develop in vivo novel adeno-associated viral (AAV) based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets. 28 March 2019
US biotech major Gilead Sciences today announced HepConnect, a five-year, multi-million dollar initiative aimed at addressing the sharp increase in chronic hepatitis C (HCV) infections fueled by the nation’s opioid crisis. 28 March 2019
Merck KGaA today announced an investment of 150 million euros ($169 million) in its manufacturing site at Aubonne, Switzerland, to expand manufacturing capacity for its biotech medicines. 28 March 2019
Ringing the opening bell at the Nasdaq stock exchange on Wednesday, Lille-based biotech Genfit (EPA: GNFT) celebrated its listing in New York, raising 130 million euros ($146 million) in the process. 28 March 2019
Aldeyra Therapeutics has announced positive results from the Phase III ALLEVIATE trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. 27 March 2019
Leaders at Swiss pharma giant Novartis hope that 2019 could see the launch of up to four new drugs that go on to become blockbusters, and the first of these won an approval in the USA on Tuesday. 27 March 2019
US biotech RegeneRx Biopharmaceuticals and Lee's Pharmaceutical, a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. 27 March 2019
On Tuesday, Israeli biotech Can-Fite BioPharma announced disappointing trial results for its orphan drug candidate namodenoson, but found a good news story hidden in the secondary endpoints. 27 March 2019
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. 26 March 2019
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah (tisagenlecleucel) for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and CD19-positive r/r diffuse large B-cell lymphoma (DLBCL). 26 March 2019
Smyraf (peficitinib hydrobromide) 50mg and 100mg tablets, an oral Janus kinase (JAK) inhibitor, received manufacturing and marketing approval in Japan for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have an inadequate response to conventional therapies. 26 March 2019
US biotech major Celgene has re-submitted a New Drug Application to the US Food and Drug Administration for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). 26 March 2019
Teijin Pharma, the core company of the Teijin Group’s healthcare business, announced today that it has acquired marketing approval for Revcovi (elapegademase [genetical recombination]) from the Ministry of Health, Labor and Welfare (MHLW). 26 March 2019
Thermo Fisher Scientific has reached a definitive agreement to acquire Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, with the news nudging its share 1.26% higher to $267.13 in early afternoon trading on Monday. 26 March 2019